

# NEUROMETHODS

*Series Editor*  
**Wolfgang Walz**  
**University of Saskatchewan**  
**Saskatoon, SK, Canada**

For further volumes:  
<http://www.springer.com/series/7657>

*Neuromethods* publishes cutting-edge methods and protocols in all areas of neuroscience as well as translational neurological and mental research. Each volume in the series offers tested laboratory protocols, step-by-step methods for reproducible lab experiments and addresses methodological controversies and pitfalls in order to aid neuroscientists in experimentation. *Neuromethods* focuses on traditional and emerging topics with wide-ranging implications to brain function, such as electrophysiology, neuroimaging, behavioral analysis, genomics, neurodegeneration, translational research and clinical trials. *Neuromethods* provides investigators and trainees with highly useful compendiums of key strategies and approaches for successful research in animal and human brain function including translational “bench to bedside” approaches to mental and neurological diseases.

# **Clinical Trials In Parkinson's Disease**

Edited by

**Santiago Perez-Lloret**

*National Research Council (CAECHIS-UAI), Buenos Aires, Argentina*

*Editor*

Santiago Perez-Lloret  
National Research Council (CAECHIS-UAI)  
Buenos Aires, Argentina

ISSN 0893-2336

ISSN 1940-6045 (electronic)

Neuromethods

ISBN 978-1-0716-0911-8

ISBN 978-1-0716-0912-5 (eBook)

<https://doi.org/10.1007/978-1-0716-0912-5>

© Springer Science+Business Media, LLC, part of Springer Nature 2021

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Humana imprint is published by the registered company Springer Science+Business Media, LLC, part of Springer Nature.

The registered company address is: 1 New York Plaza, New York, NY 10004, U.S.A.

---

## **Dedication**

To my wife and children, whose endless support was essential for the completion of this book.

---

## Preface to the Series

Experimental life sciences have two basic foundations: concepts and tools. The *Neuromethods* series focuses on the tools and techniques unique to the investigation of the nervous system and excitable cells. It will not, however, shortchange the concept side of things as care has been taken to integrate these tools within the context of the concepts and questions under investigation. In this way, the series is unique in that it not only collects protocols but also includes theoretical background information and critiques which led to the methods and their development. Thus it gives the reader a better understanding of the origin of the techniques and their potential future development. The *Neuromethods* publishing program strikes a balance between recent and exciting developments like those concerning new animal models of disease, imaging, in vivo methods, and more established techniques, including, for example, immunocytochemistry and electrophysiological technologies. New trainees in neurosciences still need a sound footing in these older methods in order to apply a critical approach to their results.

Under the guidance of its founders, Alan Boulton and Glen Baker, the *Neuromethods* series has been a success since its first volume published through Humana Press in 1985. The series continues to flourish through many changes over the years. It is now published under the umbrella of Springer Protocols. While methods involving brain research have changed a lot since the series started, the publishing environment and technology have changed even more radically. Neuromethods has the distinct layout and style of the Springer Protocols program, designed specifically for readability and ease of reference in a laboratory setting.

The careful application of methods is potentially the most important step in the process of scientific inquiry. In the past, new methodologies led the way in developing new disciplines in the biological and medical sciences. For example, Physiology emerged out of Anatomy in the nineteenth century by harnessing new methods based on the newly discovered phenomenon of electricity. Nowadays, the relationships between disciplines and methods are more complex. Methods are now widely shared between disciplines and research areas. New developments in electronic publishing make it possible for scientists that encounter new methods to quickly find sources of information electronically. The design of individual volumes and chapters in this series takes this new access technology into account. Springer Protocols makes it possible to download single protocols separately. In addition, Springer makes its print-on-demand technology available globally. A print copy can therefore be acquired quickly and for a competitive price anywhere in the world.

*Saskatoon, SK, Canada*

*Wolfgang Walz*

---

## Preface

Parkinson's disease is the second most frequent neurodegenerative disorder after Alzheimer's disease. Parkinson's disease is considered by many authors as a pandemic. Indeed, the prevalence of this disease, and thus disability and deaths owing to it, more than doubled from 1990 to 2015. The Global Burden of Disease Study estimated that 6.2 million individuals had Parkinson's disease in 2018. The number of affected persons will likely reach 14.2 million in 2040.

Parkinson's disease seriously affects quality of life. Indeed, the disease has a profound and progressive impact on various neurological functions. Motor symptoms such as bradykinesia, rigidity, and tremor are the cardinal symptoms of the disease. Notwithstanding, quality of life is more affected by non-motor symptoms. Patients with Parkinson's disease are frequently affected by cognitive impairment, mood disorders, autonomic disturbances, troubled sleep, and sensory symptoms. Therefore, both motor and non-motor symptoms need to be treated in order to achieve satisfactory quality of life in patients with Parkinson's disease.

Randomized, controlled, double-blinded clinical trials are the cornerstone of the assessment of drugs and medical devices efficacy and safety. Randomization reduces the possibility of selection bias, by assigning trial participants to treatments groups on a random basis. Double blind permits effective allocation concealment and reduces the risk of performance, attrition, and detection bias. Respectively, these biases occur when there are systematic differences between groups in the care that is provided or in exposure to factors other than the interventions of interest, or in withdrawals from a study, or in how outcomes are determined.

This book reviews major clinical trials for motor and non-motor symptoms in Parkinson's disease and discusses their most important aspects, including study designs, sample selection, and outcome selection. Therefore, it aids clinicians and researchers to better interpret results from clinical trials in Parkinson's disease and to design their own high-quality trials.

*Buenos Aires, Argentina*

*Santiago Perez-Lloret*

---

# Contents

<i>Dedication</i> . . . . .	<i>v</i>
<i>Preface to the Series</i> . . . . .	<i>vii</i>
<i>Preface</i> . . . . .	<i>ix</i>
<i>Contributors</i> . . . . .	<i>xiii</i>

## PART I PRECLINICAL MODELS OF PARKINSON'S DISEASE

1 Toxin-Based Rodent Models of Parkinson's Disease . . . . .	3
<i>M. Angela Cenci and Véronique Sgambato</i>	
2 Assessment of Nonmotor Symptoms in Rodent Models of Parkinson's Disease . . . .	21
<i>Francesca Rossi, Manolo Carta, and Elisabetta Tronci</i>	
3 Genetic Models of Parkinson's Disease . . . . .	37
<i>Philippe Kachidian and Paolo Gubellini</i>	

## PART II CLINICAL TRIALS FOR MOTOR SYMPTOMS IN PARKINSON'S DISEASE

4 A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson's Disease Patients and Quality of Evidence Recommendations . . . . .	87
<i>Mónica M. Kurtis, Carmen Rodriguez-Blazquez, and Isabel Pareés</i>	
5 Clinical Trials for Motor Complications in Parkinson's Disease . . . . .	109
<i>Tiago A. Mestre, Joaquim J. Ferreira, and Olivier Rascol</i>	
6 Clinical Trials for Gait Disorders in Parkinson's Disease . . . . .	137
<i>Zuzana Kosutzka, Urban M. Fietzek, and Peter Valkovic</i>	
7 Clinical Trials for Disease-Modifying Agents in Parkinson's Disease. . . . .	161
<i>Orlando Artavia and Lana Chahine</i>	
8 Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson's Disease. . . . .	177
<i>Santiago Perez-Lloret, James A. G. Crispo, Maria Veronica Rey, Donald Mattison, and Daniel Krewski</i>	

## PART III CLINICAL TRIALS FOR NONMOTOR SYMPTOMS IN PARKINSON'S DISEASE

9 Clinical Trials for Cognitive Impairment and Dementia in Parkinson's Disease . . . .	193
<i>Brandon Barton</i>	
10 Clinical Trials for Depression, Anxiety, Fatigue, and Apathy in Parkinson's Disease. . . . .	227
<i>Matej Skorvanek and Marek Balaz</i>	



11	Clinical Trials for Sleep Disorders and Daytime Somnolence in Parkinson's Disease. . . . .	271
	<i>Marissa N. Dean and Amy W. Amara</i>	
12	Clinical Trials on Management of Pain in Parkinson's Disease . . . . .	293
	<i>Azman Aris, Katarina Rukavina, Raquel Taddei, Alexandra Rizos, Anna Sauerbier, and K. Ray Chaudhuri</i>	
13	Clinical Trials for Orthostatic Hypotension in Parkinson's Disease and Other Synucleinopathies. . . . .	323
	<i>Jose-Alberto Palma and Horacio Kaufmann</i>	
14	Clinical Trials for Erectile Dysfunction in Parkinson's Disease . . . . .	367
	<i>Shen-Yang Lim, Ai Huey Tan, and Mathis Grossmann</i>	
15	Clinical Trials for Constipation in Parkinson's Disease . . . . .	379
	<i>Patricio Millar Verneti</i>	
	<i>Index . . . . .</i>	395

---

## Contributors

- AMY W. AMARA • *Division of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA*
- AZMAN ARIS • *Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK*
- ORLANDO ARTAVIA • *Burrell College of Osteopathic Medicine, Eastern New Mexico Medical Center, Roswell, NM, USA*
- MAREK BALAZ • *Department of Neurology, St. Anne's University Hospital, Masaryk University, Brno, Czech Republic*
- BRANDON BARTON • *Parkinson Disease and Movement Disorder Section, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; Neurology Service, Jesse Brown VA Medical Center, Chicago, IL, USA*
- MANOLO CARTA • *Department of Biomedical Sciences, Section of Physiology, University of Cagliari, Cittadella Universitaria, Monserrato, Italy*
- M. ANGELA CENCI NILSSON • *Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden*
- LANA CHAHINE • *Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA*
- K. RAY CHAUDHURI • *Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; National Parkinson Foundation, Centre of Excellence, Kings College Hospital, London, UK*
- JAMES A. G. CRISPO • *Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Division of Human Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada*
- MARISSA N. DEAN • *Division of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA*
- JOAQUIM J. FERREIRA • *Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Instituto de Medicina Molecular, Lisboa, Portugal; Campus Neurológico Sénior (CNS), Torres Vedras, Portugal*
- URBAN M. FIETZEK • *Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany; Department of Neurology and Clinical Neurophysiology, Schön Klinik München Schwabing, Munich, Germany*
- MATHIS GROSSMANN • *Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Endocrinology, Austin Health, Melbourne, VIC, Australia*
- PAOLO GUBELLINI • *Aix-Marseille Univ., CNRS (Centre National de la Recherche Scientifique), IBDM (Institut de Biologie du Développement de Marseille) UMR7288, Marseille, France*
- PHILIPPE KACHIDIAN • *Aix-Marseille Univ., CNRS (Centre National de la Recherche Scientifique), IBDM (Institut de Biologie du Développement de Marseille) UMR7288, Marseille, France*

- HORACIO KAUFMANN • *Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA*
- ZUZANA KOSUTZKA • *Second Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia*
- DANIEL KREWSKI • *School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; Risk Sciences International, Ottawa, ON, Canada*
- MÓNICA M. KURTIS • *Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain*
- SHEN-YANG LIM • *Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; The Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, University of Malaya, Kuala Lumpur, Malaysia; Neurology Laboratory, University of Malaya Medical Centre, Kuala Lumpur, Malaysia*
- DONALD MATTISON • *School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; Risk Sciences International, Ottawa, ON, Canada*
- TIAGO A. MESTRE • *Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada*
- JOSE-ALBERTO PALMA • *Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA*
- ISABEL PARÉÉS • *Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain; Movement Disorders Unit, Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain*
- SANTIAGO PEREZ-LLORET • *Center for Biomedical Research (CAECHIS), Universidad Abierta Interamericana, CONICET, Buenos Aires, Argentina; Department of Physiology, School of Medicine, University of Buenos Aires (UBA), Buenos Aires, Argentina; School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), Buenos Aires, Argentina*
- OLIVIER RASCOL • *Department of Clinical Pharmacology and Neurosciences, University Hospital and University of Toulouse 3, Toulouse, France; INSERM CIC1436 and UMR825, Toulouse, France*
- MARIA VERONICA REY • *Center for Biomedical Research (CAECHIS), Universidad Abierta Interamericana, CONICET, Buenos Aires, Argentina*
- ALEXANDRA RIZOS • *Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK; Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College Hospital, King's College, London, UK*
- CARMEN RODRIGUEZ-BLAZQUEZ • *National Center of Epidemiology and CIBERNED, Institute of Health Carlos III, Madrid, Spain*
- FRANCESCA ROSSI • *Department of Biomedical Sciences, Section of Physiology, University of Cagliari, Cittadella Universitaria, Monserrato, Italy*
- KATARINA RUKAVINA • *Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; National Parkinson Foundation, Centre of Excellence, Kings College Hospital, London, UK*

- ANNA SAUERBIER • *Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College Hospital, King's College, London, UK*
- VÉRONIQUE SGAMBATO • *University of Lyon, CNRS UMR 5229, Marc Jeannerod Institut of Cognitive Sciences, Bron, France*
- MATEJ SKORVANEC • *Department of Neurology, Faculty of Medicine, P. J. Safarik University, Kosice, Slovakia; Department of Neurology, University Hospital L. Pasteur, Kosice, Slovakia*
- RAQUEL TADDEI • *Maurice Wohl Clinical Neuroscience Institute and NIHR Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College Hospital, King's College, London, UK*
- AI HUEY TAN • *Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; The Mah Pooi Soo and Tan Chin Nam Centre for Parkinson's and Related Disorders, University of Malaya, Kuala Lumpur, Malaysia*
- ELISABETTA TRONCI • *Department of Biomedical Sciences, Section of Physiology, University of Cagliari, Cittadella Universitaria, Monserrato, Italy*
- PETER VALKOVIC • *Second Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia; Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia*
- PATRICIO MILLAR VERNETTI • *Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA*